A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Germany
Latest Information Update: 30 Sep 2022
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PIONEER REAL
- Sponsors Novo Nordisk
Most Recent Events
- 27 Sep 2022 Planned initiation date changed from 1 Sep 2022 to 30 Sep 2022.
- 27 Sep 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Jul 2022 New trial record